Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study

Abstract Background Erenumab is a monoclonal antibody (mAb) against the calcitonin gene related peptide (CGRP) receptor and is commonly used in migraine prophylaxis. Pivotal and open-label studies show a good safety and tolerability. However, little is known about possible predictors, dose dependenc...

Full description

Bibliographic Details
Main Authors: Hannah Schenk, Dagny Holle, Michael Nsaka, Christoph Kleinschnitz, Martin Glas, Armin Scheffler
Format: Article
Language:English
Published: BMC 2022-05-01
Series:The Journal of Headache and Pain
Subjects:
CGRP antibody
Erenumab
Migraine
Safety and tolerability
Adverse event
Real-world
Online Access:https://doi.org/10.1186/s10194-022-01426-8

Internet

https://doi.org/10.1186/s10194-022-01426-8

Similar Items